RxDoctor Payments Data

Allison Angott, MD

Family Medicine · Rocky Mount, NCNPI 1972579944

Payments from drug & device makers

$5,212in general payments, 2019–2025

Across 352 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$979
  • AstraZeneca$543
  • Amgen$539
  • Boehringer Ingelheim$292
  • Pfizer$289
  • AbbVie$286
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,191100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,212 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,781
Medicare patients
116
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$28,640
OzempicSemaglutide25$26,368
ShingrixVaricella-Zoster Ge/As01b/Pf90$19,950
Repatha SureclickEvolocumab16$18,268
JanuviaSitagliptin Phosphate11$8,215
Boostrix TdapDiphth,pertuss(Acell),tet Vac94$6,518
AbrysvoRsv Vacc, Pref A And Pref B/Pf20$6,308
SynthroidLevothyroxine Sodium15$1,459
Atorvastatin Calcium173$1,445
Ezetimibe73$1,203
Gabapentin57$961
Albuterol Sulfate HfaAlbuterol Sulfate21$732
Pravastatin Sodium31$641
Pantoprazole Sodium49$610
Potassium Chloride33$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$289$34,94948 claims
Novo NordiskOzempic$979$26,36825 claims
GSKShingrix$256$19,95090 claims
MerckJanuvia$185$8,21511 claims
AbbVieSynthroid$286$1,45915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →